Illustrative image.
Exjade
Deferasirox
$416.00
125mg · 28 tablets
BrandBranded medicine· By Sandoz
Strength
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
125mg
250mg
500mg
FDA boxed warningRenal failure, hepatic failure, and gastrointestinal hemorrhage
Renal Failure
Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m
Hepatic Failure
Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.
Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh B) hepatic impairment.
Gastrointestinal Hemorrhage
Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.
Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage.
Deferasirox may cause:
hepatic toxicity, including failure
Deferasirox therapy requires close patient monitoring, including laboratory tests of renal and hepatic function.
About Exjade
Overview
Exjade contains deferasirox, a prescription iron-chelating medicine. It treats long-term iron overload caused by blood transfusions in patients aged 2 years and older. It also treats long-term iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia when liver iron concentration is at least 5 mg per gram of dry weight and serum ferritin is greater than 300 mcg/L. It works by binding to iron in the body.
What it treats
- Chronic iron overload caused by blood transfusions in patients aged 2 years and older. - Chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT), a liver iron concentration of at least 5 mg of iron per gram of dry weight, and serum ferritin greater than 300 mcg/L.
Safety information
Side effects
Common side effects include diarrhea, nausea, vomiting, abdominal pain and skin rash. Increased blood creatinine, a possible sign of kidney problems, is also common in patients with iron overload from transfusions. In patients with non-transfusion-dependent thalassemia (NTDT), the most common side effects are diarrhea, rash and nausea. Serious side effects that warrant contacting a doctor include kidney injury or failure, sometimes requiring dialysis; damage to the kidney’s filtering tubes, including Fanconi syndrome; liver damage or failure; and stomach or intestinal bleeding, ulcers or irritation. Gastrointestinal bleeding can be fatal, and the risk may be greater when deferasirox is taken with medicines that can cause ulcers or bleeding. Other serious risks include reduced blood cell counts, including low white blood cells, worsening anemia and low platelets; severe allergic reactions; severe skin reactions such as Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS; and hearing or eye problems. Some blood cell disorders have been fatal. Severe allergic or skin reactions require stopping deferasirox and seeking immediate medical attention. Kidney function, liver function and blood counts need monitoring during treatment. Children and older adults need close monitoring for toxicity.
FDA boxed warning
Renal failure, hepatic failure, and gastrointestinal hemorrhage
Renal Failure
Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m
Hepatic Failure
Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.
Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh B) hepatic impairment.
Gastrointestinal Hemorrhage
Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.
Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage.
Deferasirox may cause:
hepatic toxicity, including failure
Deferasirox therapy requires close patient monitoring, including laboratory tests of renal and hepatic function.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Exjade (deferasirox) if you have: • Severely reduced kidney function (estimated GFR below 40 mL/min/1.73 m²). • Poor overall functional status. • High-risk myelodysplastic syndromes (MDS). • Advanced cancer. • A platelet count below 50 × 10⁹/L. • A known allergy to deferasirox or any ingredient in the tablets. Exjade can cause serious kidney injury, liver toxicity, stomach or intestinal ulcers and bleeding, and reduced blood cell counts. Some bleeding events and blood cell disorders have been fatal. Kidney function must be checked before treatment and monitored during treatment, along with liver function and blood counts. Toxicity may require your prescriber to adjust or interrupt treatment. Extra caution is needed if you take medicines that can cause ulcers or increase bleeding risk. Older adults and children need close monitoring for toxicity. Severe allergic reactions or severe skin reactions, including Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS, require stopping treatment and seeking medical attention. Do not breastfeed during treatment.
Interactions
Do not take Exjade (deferasirox) with antacids containing aluminum. Tell your doctor if you take: • Repaglinide: deferasirox can increase exposure to this medicine. Your doctor may need to reduce your repaglinide dose and monitor your blood glucose. • Theophylline: use with deferasirox should be avoided. • Busulfan: deferasirox can increase exposure to this medicine. Your doctor should monitor busulfan levels in your blood and adjust treatment if needed.
Using Exjade
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label DEFERASIROX TABLET, FOR SUSPENSION [TEVA PHARMACEUTICALS, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
NovoEight
Antihemophilic Factor (recombinant)
By Novo Nordisk
Pack · from 1 per pack
Also for blood disorders
Brand $1,034.00
Koāte‑DVI
Antihemophilic Factor (human) (factor Viii)
By Grifols
Vial · from 1 per pack
Also for blood disorders
Brand $1,034.00
RhoGAM
Anti‑d (rh₀) Immunoglobulin (human)
By Kamada
Vial · from 1 per pack
Also for blood disorders
Brand $150.00
Ferriprox
Deferiprone
By None
Tablets · from 100 per pack
Also for blood disorders
Brand $377.00